| Literature DB >> 31068434 |
Rachel L Darnell1,2, Melanie K Knottenbelt1, Francesca O Todd Rose1, Ian R Monk3, Timothy P Stinear3, Gregory M Cook4,2.
Abstract
Teixobactin is a new antimicrobial of significant interest. It is active against a number of multidrug-resistant pathogens, including Staphylococcus aureus and Enterococcus faecalis, with no reported mechanisms of teixobactin resistance. However, historically, mechanisms of resistance always exist and arise upon introduction of a new antimicrobial into a clinical setting. Therefore, for teixobactin to remain effective long term, we need to understand how mechanisms of resistance could develop. Here we demonstrate that E. faecalis shows a remarkable intrinsic tolerance to high concentrations of teixobactin. This is of critical importance, as antimicrobial tolerance has been shown to precede the development of antimicrobial resistance. To identify potential pathways responsible for this tolerance, we determined the genomewide expression profile of E. faecalis strain JH2-2 in response to teixobactin using RNA sequencing. A total of 573 genes were differentially expressed (2.0-fold log2 change in expression) in response to teixobactin, with genes involved in cell wall biogenesis and division and transport/binding being among those that were the most upregulated. Comparative analyses of E. faecalis cell wall-targeting antimicrobial transcriptomes identified CroRS, LiaRS, and YclRK to be important two-component regulators of antimicrobial-mediated stress. Further investigation of CroRS demonstrated that deletion of croRS abolished tolerance to teixobactin and to other cell wall-targeting antimicrobials. This highlights the crucial role of CroRS in controlling the molecular response to teixobactin.IMPORTANCE Teixobactin is a new antimicrobial with no known mechanisms of resistance. Understanding how resistance could develop will be crucial to the success and longevity of teixobactin as a new potent antimicrobial. Antimicrobial tolerance has been shown to facilitate the development of resistance, and we show that E. faecalis is intrinsically tolerant to teixobactin at high concentrations. We subsequently chose E. faecalis as a model to elucidate the molecular mechanism underpinning teixobactin tolerance and how this may contribute to the development of teixobactin resistance.Entities:
Keywords: CroRS; Enterococcuszzm321990; RNA sequencing; antimicrobial resistance; antimicrobial tolerance; mechanisms of resistance; teixobactin
Mesh:
Substances:
Year: 2019 PMID: 31068434 PMCID: PMC6506618 DOI: 10.1128/mSphere.00228-19
Source DB: PubMed Journal: mSphere ISSN: 2379-5042 Impact factor: 4.389
Teixobactin MICs and MBCs for S. aureus and E. faecalis
| Strain | Antimicrobial | MIC (μg ml−1) | MBC (μg ml−1) |
|---|---|---|---|
| Teixobactin | 2 | 2 | |
| Teixobactin | 2 | 16 | |
| Vancomycin | 1 | >128 | |
| Bacitracin | 32 | 64 | |
| Ampicillin | 0.5 | 2 | |
| Penicillin G | 2 | 2 | |
| Daptomycin | 2 | 4 |
Mean MICs and MBCs for at least three biological replicates are reported.
S. aureus strain ATCC 6538 and E. faecalis strain JH2-2.
FIG 1Time-dependent kill kinetic assay of S. aureus and E. faecalis upon teixobactin challenge. Strains were grown to mid-exponential phase (5 × 108 CFU ml−1) and untreated or challenged with 50× MIC of teixobactin. Cell survival (number of CFU ml−1) was measured at time zero and 1, 2, 3, 4, 6, and 24 h postchallenge. Results are the mean ± SD (data are for biological triplicates).
FIG 2Pie charts showing the distribution of gene ontologies up- and downregulated in response to teixobactin. recomb., recombination.
The 20 most up- and downregulated genes in response to teixobactin in E. faecalis V583 and JH2-2
| Gene regulation | Gene in | Gene name | F/C | Function | |
|---|---|---|---|---|---|
| V583 | JH2-2 | ||||
| Upregulated | EF1518 | 1316 | 9.5 | Soluble lytic murein transglycosylase | |
| EF0443 | 2523 | 8.7 | Endopeptidase | ||
| EF1533 | 1329 | 7.9 | Conserved hypothetical protein | ||
| EF0802 | 545 | 7.8 | DUF3955 domain-containing protein | ||
| EF1665 | 1454 | 7.6 | Conjugal transfer protein TraX | ||
| EF1231 | 1016 | 7.6 | Metallophosphoesterase | ||
| EF2896 | 2418 | 7.2 | DUF3955 domain-containing protein | ||
| EF0932 | 663 | 7.1 | Hypothetical protein | ||
| EF2986 | 287 | 6.8 | ABC transporter ATP-binding protein | ||
| EF2050 | 1817 | 6.3 | Peptide ABC transporter: ATP-binding protein | ||
| EF2987 | 286 | 6.3 | RND transporter | ||
| EF1532 | 1328 | 6.2 | Hypothetical protein | ||
| EF0038 | 2863 | 6.2 | Glutamate-5-kinase | ||
| EF2771 | 2347 | 6.0 | TraX family protein | ||
| EF1258 | 1042 | 6.0 | Hypothetical protein | ||
| EF2214 | 1918 | 5.8 | VOC family protein | ||
| EF1198 | 982 | 5.7 | ABC transporter permease | ||
| EF0737 | 484 | 5.5 | Amidase | ||
| EF2211 | 1915 | 5.4 | YxeA family protein | ||
| EF0680 | 422 | 5.4 | Penicillin binding protein 1A | ||
| Downregulated | EF0411 | 2555 | −11.6 | PTS mannitol transporter subunit IICB | |
| EF3139 | 138 | −10.9 | PTS sugar transporter subunit IIC | ||
| EF0412 | 2554 | −10.2 | PTS mannitol transporter subunit IIA | ||
| EF3141 | 136 | −9.9 | 2-Hydroxyacid dehydrogenase | ||
| EF2965 | 2466 | −9.9 | PTS sugar transporter subunit IIB | ||
| EF3142 | 135 | −9.7 | 6-Phosphogluconate dehydrogenase | ||
| EF0413 | 2553 | −9.7 | Mannitol-1-phosphate 5-dehydrogenase | ||
| EF3213 | 69 | −9.6 | PTS mannose transporter subunit IID | ||
| EF3140 | 137 | −9.4 | Oxidoreductase | ||
| EF3211 | 71 | −9.4 | PTS mannose/fructose/sorbose/ | ||
| EF2966 | 2467 | −9.3 | MltR-like mannitol-operon transcriptional regulator | ||
| EF2582 | 2168 | −9.0 | Chlorohydrolase/aminohydrolase | ||
| EF3138 | 139 | −9.0 | PTS mannose transporter subunit IID | ||
| EF2964 | 2465 | −8.9 | PTS ascorbate transporter subunit IIC | ||
| EF2223 | 1927 | −8.8 | ABC transporter family | ||
| EF3212 | 70 | −8.7 | PTS mannose/fructose/sorbose/ | ||
| EF3327 | 2909 | −8.7 | Citrate transporter | ||
| EF3210 | 72 | −8.6 | PTS mannose/fructose/sorbose/ | ||
| EF1031 | 742 | −8.4 | PTS sugar transporter subunit IIC | ||
| EF1207 | 991 | −8.4 | |||
F/C, log2 fold change.
Cell antimicrobial MICs and MBCs for the E. faecalis JH2-2 wild type and ΔcroRS mutant
| Antimicrobial | WT | Δ | ||
|---|---|---|---|---|
| MIC (μg ml−1) | MBC (μg ml−1) | MIC (μg ml−1) | MBC (μg ml−1) | |
| Teixobactin | 1 | 16 | 1 | 1 |
| Vancomycin | 1 | >128 | 1 | 1–2 |
| Bacitracin | 32 | 64 | 16 | 16 |
| Ampicillin | 0.5 | 2 | 0.5 | 2 |
| Gentamicin | 32 | 32 | 8 | 8 |
Mean MICs and MBCs for at least three biological replicates are reported. Where the MBC values for the biological replicates differed, the MBC ranges are shown. WT, wild type.
FIG 3Time-dependent kill kinetic assay of the E. faecalis JH2-2 wild type and ΔcroRS mutant. Strains were grown to mid-exponential phase (5 × 108 CFU ml−1) and untreated or challenged with 25× or 50× MIC of teixobactin (Tx) and vancomycin (Van), respectively. Cell survival (number of CFU ml−1) was measured at time zero and 1, 2, 3, 4, 6, 8, and 24 h postchallenge. Results are the mean ± SD (data are for biological triplicates).